How Much Does Vyleesi (Bremelanotide) Cost in South Carolina in 2026?

Retail Price of Vyleesi at South Carolina Pharmacies

The average cash-pay price for brand-name Vyleesi across South Carolina retail pharmacies sits at roughly $1,200 per month in 2026. This figure reflects the manufacturer list price set by Palatin Technologies and has remained largely stable since the drug's FDA approval in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Each Vyleesi autoinjector delivers a 1.75 mg subcutaneous dose of bremelanotide. Patients self-administer the injection approximately 45 minutes before anticipated sexual activity. The FDA label specifies a maximum of one dose per 24-hour period and no more than eight doses in a calendar month. At that upper bound of eight injections monthly, the per-dose cost works out to $150 from retail pharmacies. Patients who use fewer doses per month will spend proportionally less, though most pharmacies in South Carolina dispense the drug as a monthly supply regardless of actual injection frequency.

Pricing can vary by $50 to $100 depending on the specific pharmacy. Independent pharmacies in Columbia, Charleston, and Greenville may offer slightly different cash-pay rates than chain retailers such as CVS, Walgreens, or Walmart. Calling ahead to compare quotes is a practical first step. GoodRx and similar discount aggregators sometimes list coupons that bring the price down marginally, but for a specialty medication like Vyleesi, the savings tend to be modest compared to what insurance or compounding pharmacies can offer.

South Carolina Medicaid and Vyleesi Coverage

South Carolina Medicaid does not cover Vyleesi. This exclusion applies across all Medicaid managed care plans operating in the state, including Healthy Blue, Molina Healthcare of South Carolina, and Select Health of South Carolina.

The non-coverage status is consistent with most state Medicaid programs nationwide. HSDD treatments are frequently classified as lifestyle medications under Medicaid formulary rules, which places them in the same exclusion category as drugs for erectile dysfunction. The Endocrine Society's clinical practice guidelines recognize HSDD as a legitimate medical condition with neurobiological underpinnings, but Medicaid formulary committees in South Carolina have not yet incorporated this perspective into their coverage determinations.

Patients enrolled in SC Medicaid who want access to bremelanotide have two practical alternatives. The first is compounded bremelanotide through a licensed 503A pharmacy, paid out of pocket at roughly $140 per month. The second is appealing through a Medicaid exception process, though approval rates for HSDD medications remain low. A treating clinician can submit documentation of prior failed therapies and clinical necessity, but patients should prepare for the likelihood of denial.

Commercial Insurance Coverage in South Carolina

Several commercial insurance plans available in South Carolina do cover Vyleesi, though almost all require prior authorization and step therapy documentation. BlueCross BlueShield of South Carolina, the state's largest private insurer, may cover Vyleesi under its specialty pharmacy tier after the prescriber demonstrates that non-pharmacological interventions (such as counseling or therapy) were attempted first.

The prior authorization process typically requires three elements: a confirmed HSDD diagnosis using validated screening tools like the Decreased Sexual Desire Screener, documentation that the condition is acquired and generalized rather than situational, and evidence that the patient is premenopausal. Some plans also require documentation that psychological or relationship factors have been addressed.

Copay amounts vary widely. Patients with commercial insurance that places Vyleesi on a specialty tier can expect copays ranging from $50 to $250 per month, depending on plan design. High-deductible health plans may require full out-of-pocket payment until the deductible is met. Patients on ACA marketplace plans purchased through healthcare.gov in South Carolina should check whether their specific metal-tier plan includes Vyleesi on the formulary, as coverage is not standardized across all marketplace options.

Calling the number on the back of your insurance card and asking the pharmacy benefits team specifically about bremelanotide coverage is the most reliable way to get a definitive answer before filling the prescription.

Compounded Bremelanotide in South Carolina: Legality and Pricing

Compounded bremelanotide is legal and available in South Carolina through licensed 503A compounding pharmacies. This represents the most significant cost-saving option for patients in the state, with prices averaging approximately $140 per month compared to $1,200 for the brand-name product.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions. In South Carolina, the Board of Pharmacy regulates these facilities under Title 40, Chapter 43 of the South Carolina Code. A compounding pharmacy must hold a valid SC pharmacy license and comply with USP 797 sterile compounding standards to prepare injectable bremelanotide.

The compounded product is not FDA-approved. It contains the same active pharmaceutical ingredient but may differ in formulation, delivery device, and excipients. Brand-name Vyleesi uses a proprietary autoinjector, while compounded versions are typically dispensed in vials for use with standard insulin syringes. Patients should understand this distinction.

The RECONNECT phase 3 trials that supported FDA approval studied only the branded formulation. In RECONNECT (N=1,247), bremelanotide 1.75 mg produced a statistically significant increase of approximately 0.5 in the number of satisfying sexual events per month compared to placebo, along with meaningful reductions in distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (Kingsberg et al., Obstet Gynecol 2019) [1]. The compounded version has not undergone separate clinical trials, so efficacy and safety data are extrapolated rather than directly demonstrated.

To obtain compounded bremelanotide in South Carolina, a patient needs a valid prescription from a licensed prescriber. Several telehealth platforms and local clinicians can write this prescription. The pharmacy then compounds the medication per the individual order. Turnaround time is typically 3 to 7 business days, and the medication is shipped directly to the patient with cold-chain packaging to maintain stability.

Telehealth Access to Vyleesi in South Carolina

South Carolina permits telehealth prescribing of Vyleesi and compounded bremelanotide. State law does not require an in-person visit prior to prescribing controlled or non-controlled medications via telemedicine, and bremelanotide is not a scheduled substance under the DEA's Controlled Substances Act.

This is a meaningful access point. Patients in rural areas of South Carolina, particularly in the Pee Dee region, Lowcountry, and Upstate counties with fewer specialists, can consult with a clinician experienced in HSDD management without traveling to Charleston or Columbia.

The typical telehealth visit for an HSDD evaluation takes 20 to 30 minutes. The clinician will review symptoms, screen for contributing factors (depression, medication side effects, hormonal status, relationship dynamics), and determine whether bremelanotide is appropriate. The International Society for the Study of Women's Sexual Health (ISSWSH) recommends a biopsychosocial assessment before initiating pharmacotherapy for HSDD [2].

Multiple national telehealth platforms serve South Carolina patients specifically for sexual health. Consultation fees range from $50 to $199 for an initial visit. Some platforms bundle the consultation fee with the compounded medication, which can simplify the process and reduce total cost. Patients should verify that the prescribing clinician holds an active South Carolina medical license, as this is required for the prescription to be valid in the state.

The Palatin Technologies Savings Card

Palatin Technologies, the manufacturer of Vyleesi, offers a savings card program that can reduce out-of-pocket costs for commercially insured patients in South Carolina. The card is not available to patients covered by government insurance programs including Medicare, Medicaid, Tricare, or VA benefits.

Eligible patients can register through the Vyleesi website. The savings card typically covers a portion of the copay or coinsurance after insurance processes the claim. Exact savings vary based on the patient's insurance plan design and formulary tier placement. Some patients report reducing their monthly out-of-pocket from $200 or more down to $25 to $50 with the card.

The program has specific terms that patients should review. Most manufacturer copay cards have annual caps on total savings, and the benefit resets each calendar year. The card may also have expiration dates or eligibility requirements that change. Patients should confirm current terms directly with Palatin Technologies before relying on the savings card as a long-term cost strategy.

For uninsured patients, the savings card typically does not apply because there is no insurance claim to adjudicate against. Uninsured patients in South Carolina are generally better served by pursuing compounded bremelanotide at approximately $140 per month rather than attempting to use manufacturer discount programs on the $1,200 brand-name product.

How Vyleesi Compares to Other HSDD Treatments on Cost

Bremelanotide is one of only two FDA-approved pharmacotherapies for HSDD in premenopausal women. The other is flibanserin (Addyi), an oral daily medication. Understanding the cost comparison helps South Carolina patients make informed decisions.

Flibanserin's average retail price in South Carolina runs approximately $400 to $800 per month for the brand-name product, though generic flibanserin became available and can be found for $30 to $100 per month at some pharmacies. Compounded flibanserin is not as widely available because the oral tablet form is less amenable to compounding cost advantages than injectable bremelanotide.

The two drugs work through different mechanisms. Bremelanotide is a melanocortin receptor agonist administered as needed before sexual activity (Clayton et al., 2016) [3]. Flibanserin is a serotonin 1A agonist/2A antagonist taken daily at bedtime. The as-needed dosing of bremelanotide means patients who are sexually active infrequently may spend less per month since they use fewer doses. A patient using Vyleesi four times monthly at the compounded price of $140 per month pays roughly $35 per use.

Dr. Sheryl Kingsberg, a leading HSDD researcher at University Hospitals Cleveland Medical Center, has noted: "The choice between bremelanotide and flibanserin should be guided by patient preference for daily versus on-demand dosing, side effect profiles, and practical considerations including cost and access" [4]. This patient-centered framing is particularly relevant in South Carolina, where out-of-pocket costs may be the deciding factor for many women.

Side effect profiles differ as well. The most common adverse effect of bremelanotide is nausea, which occurred in 40% of patients in the RECONNECT trials compared to 1% with placebo [1]. The FDA label also notes transient increases in blood pressure and decreases in heart rate following injection [5]. Flibanserin carries a boxed warning about hypotension and syncope when combined with alcohol. Neither drug is approved for postmenopausal women or for men.

Practical Steps to Minimize Cost in South Carolina

Reducing what you pay for bremelanotide in South Carolina comes down to a few concrete actions. Start by checking your insurance formulary. If Vyleesi is covered, ask your prescriber to submit prior authorization with HSDD diagnosis documentation, prior treatment history, and screening tool results.

If your plan covers Vyleesi, register for the Palatin Technologies savings card to reduce your copay further. Stack that with any pharmacy discount programs your retailer offers.

If insurance does not cover Vyleesi, or if you are uninsured, request a prescription for compounded bremelanotide. Locate a 503A-licensed pharmacy in South Carolina or use a national compounding pharmacy that ships to SC addresses. The price difference between $1,200 and $140 per month is substantial enough to make compounding the default choice for most cash-pay patients.

Telehealth consultations offer a lower-cost entry point for the initial prescription compared to specialist office visits. Several platforms operating in South Carolina charge $75 to $150 for an HSDD evaluation, compared to $200 to $400 for an in-person visit with a gynecologist or sexual medicine specialist.

Patients should also ask about multi-month supply discounts. Some compounding pharmacies offer 10% to 15% reductions for three-month orders. Cold-chain shipping costs are also reduced when consolidated into fewer deliveries.

The American College of Obstetricians and Gynecologists (ACOG) recognizes HSDD as an underdiagnosed condition and supports pharmacotherapy as part of a comprehensive treatment plan that may include psychotherapy, relationship counseling, and management of contributing medical conditions [6]. Treatment cost should not be the sole barrier to care for South Carolina women experiencing clinically significant sexual desire distress.